


**Product Name** : eFT226  
**Cat. No.** : PC-63308  
**CAS No.** : 2098191-53-6  
**Molecular Formula** : C<sub>28</sub>H<sub>29</sub>N<sub>3</sub>O<sub>5</sub>  
**Molecular Weight** : 487.55  
**Target** : Eukaryotic Initiation Factor (eIF)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Zotatifin (eFT226) is a novel, potent and selective **eIF4A** inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.

Zotatifin (eFT226) selectively inhibits translation of mRNAs containing longer 5'-UTRs, an increased frequency of uORFs (upstream open reading frame), and polypurine and/or G-quadruplex recognition motifs.

Zotatifin (eFT226) demonstrates potent inhibition of reporter constructs containing a polypurine motif in the 5'-UTR with IC<sub>50</sub> of 2 nM.

Zotatifin (eFT226) shows potent anti-proliferative activity (EC<sub>50</sub><15 nM) and an induction of apoptosis against a panel of B-cell lymphoma cell lines, dose-dependently decreases the oncogenic drivers c-MYC, CCND1/3, BCL2 or MCL-1.

Zotatifin (eFT226) shows in vivo activity across hematological tumor models.

## References

Peggy A. Thompson, et al. Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-tumor Activity in B-cell Malignancies.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com